Rapid Acting Antidepressants

Part I - Neurobiology of ketamine effects - Effects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmission Allie J. Widman and Lori L. McMahon - Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition Bernhard Luscher, Mengyang Feng and Sarah J. Jefferson - The role of eEF2 kinase in the rapid antidepressant actions of ketamine Kanzo Suzuki and Lisa M. Monteggia Part II - The rapid therapeutic effects of ketamine - Clinical overview of NMDA-R antagonists and clinical practice Pasha A. Davoudian and Samuel T. Wilkinson - Ketamine for depression clinical issues Syed Z. Iqbal and Sanjay J. Mathew - Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence Lynnette A. Averill, Samar Fouda, James W. Murrough and Chadi G. Abdallah - Neurobiological biomarkers of response to ketamine Bashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter, Stephen Murata, Nimesha Gerlus and Carlos A. Zarate Jr - Relapse prevention in treatment resistant major depressive disorder with rapid-acting antidepressants Jaskaran B. Singh, Maggie Fedgchin, Ella J. Daly and Wayne C. Drevets - The emergence of ketamine as a novel treatment for posttraumatic stress disorder Adriana Feder, Sarah B. Rutter, Daniela Schille and Dennis S. Charney Part III - Novel rapid-acting antidepressant mechanisms related to ketamine - mGlu2/3 receptor as a novel target for rapid acting antidepressants Shigeyuki Chaki - Involvement of muscarinic receptor mechanisms in antidepressant drug action Jeffrey M. Witkin, Jodi L. Smith, Lalit K. Golani, Emily A. Brooks and Anna E. Martin - The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions Wayne C. Drevets, Anindya Bhattacharya and Maura L. Furey